A cancer lawsuit finder is a service, usually a website or call center, that screens people with a cancer diagnosis and routes them to law firms handling mass tort cases tied to a specific product or exposure. Some are run by law firms themselves. Many are lead-generation companies that sell your information to firms, sometimes to several at once. The quality varies widely, and so does what happens after you fill out the form. Before you use one, it helps to know what separates a serious intake operation from a claim mill, and which cancer lawsuits are actually active right now.1Research file
How to Tell a Legitimate Service From a Claim Mill
The industry runs on advertising. Between July 2015 and June 2016, more than 53,000 national drug-injury ad spots ran at a cost of roughly $114 million, with the top ten advertisers accounting for 72 percent of the volume. Many of the biggest advertisers do not litigate the cases they recruit; they refer clients to other lawyers in exchange for a share of any recovery.1Research file
That structure is legal. What makes a particular service worth avoiding is a different set of signals.
- Requests for money upfront. Cancer litigation firms work on contingency and collect only if they win or settle. A fee request before any work is done is a red flag.
- Guaranteed outcomes or specific dollar figures in the ad. No honest attorney can promise a result.
- Implied government backing. Phrases like “medical alert,” “consumer alert,” and “legal helpline” are often designed to sound official. The federal government does not employ attorneys to handle private cancer lawsuits.
- Any suggestion that you stop taking a prescribed medication. In 2019 the Federal Trade Commission sent warning letters to attorneys and lead generators whose ads were causing patients to discontinue anticoagulants. An FDA study identified 66 patients who stopped their medication after seeing lawyer ads; 33 had strokes and seven died.1Research file
Beyond the ad itself, do two checks. Confirm the attorneys who would actually handle your case are licensed and in good standing with their state bar. Then look for a documented track record in the specific litigation you’d be joining. Major verdicts and settlements are public record, and a firm that has tried or settled cases in your mass tort will say so with specifics.1Research file
Tennessee and Texas both passed laws in 2019 aimed specifically at deceptive lawsuit advertising, though enforcement varies.1Research file
Active Cancer Lawsuits by Product and Diagnosis
A cancer lawsuit finder is only useful if your diagnosis and exposure line up with litigation that’s actually being pursued. These are the major active cases.
Roundup and Non-Hodgkin Lymphoma
About 170,000 lawsuits allege that glyphosate, the active ingredient in Monsanto’s Roundup weedkiller, causes non-Hodgkin lymphoma. Bayer, which owns Monsanto, has paid nearly $11 billion in settlements, and plaintiffs have won eight jury verdicts totaling more than $6 billion since October 2023.1Research file
In February 2026, Bayer announced a new $7.25 billion settlement covering current and future claims, and a judge granted preliminary approval in early March 2026. Firms representing nearly 20,000 claimants have objected. If finalized, individual payouts would range from roughly $6,000 to $165,000, with age at diagnosis and occupational exposure driving the figure. A Supreme Court case argued April 27, 2026, Monsanto Co. v. Durnell, could reshape the litigation by deciding whether federal pesticide law preempts state failure-to-warn claims. A decision is expected by late June 2026.1Research file
Talcum Powder, Ovarian Cancer, and Mesothelioma
Johnson & Johnson faces more than 67,000 pending lawsuits alleging that its talc-based products, including Baby Powder, cause ovarian cancer and mesothelioma. The company tried three times to resolve the cases through a subsidiary’s bankruptcy, offering between $6.48 billion and $8.9 billion. All three attempts failed; the most recent, involving Red River Talc LLC, was dismissed in March 2025 after a judge cited “significant irregularities” in claimant voting.1Research file
With bankruptcy off the table, cases are moving through court. A Maryland woman with peritoneal mesothelioma won $1.5 billion in December 2025. A California mesothelioma patient’s family won $966 million in October 2025. A court-appointed mediator is working toward a global ovarian cancer settlement, and the first federal bellwether trial has been selected.1Research file
Asbestos and Mesothelioma
Asbestos litigation is the longest-running mass tort in U.S. history and remains active. In 2025, 4,244 asbestos lawsuits were filed nationally, a six percent increase over the prior year. About 40 percent of 2025 filings involved talc-related asbestos exposure, up from 17 percent in 2021.1Research file
Mesothelioma cases are filed individually rather than as class actions. Settlements typically run $1 million to $1.4 million; trial verdicts average $5 million to $11.4 million. More than 99 percent of cases settle. Beyond lawsuits, over 60 asbestos bankruptcy trust funds hold more than $30 billion for claimants, with typical combined payouts across multiple trusts of $300,000 to $400,000.1Research file
AFFF Firefighting Foam and Kidney, Testicular, Liver, and Thyroid Cancer
Lawsuits over aqueous film-forming foam containing PFAS chemicals are consolidated in a multidistrict litigation in South Carolina. The case count passed 100,000 in late 2025 before the court restricted new personal injury filings in September 2025. As of March 2026, roughly 15,220 actions were pending.1Research file
The settlements so far have gone to public water providers, not personal injury claimants: $12.5 billion from 3M, $1.185 billion from DuPont and related entities, and $750 million from Tyco Fire Products. No global personal injury settlement exists. The first personal injury bellwether, a Pennsylvania plaintiff with kidney cancer, was postponed from October 2025 and is expected to be rescheduled in 2026.1Research file
Chemical Hair Relaxers and Uterine, Ovarian, and Endometrial Cancer
More than 11,000 lawsuits allege that chemical hair straightening products from L’Oréal, Revlon, and other companies cause uterine, ovarian, and endometrial cancer. The litigation is consolidated before Judge Mary Rowland in the Northern District of Illinois. The court held a “Science Day” in January 2026, and in April 2026 the judge selected ten cases for bellwether preparation. A settlement special master has been appointed, but federal trial dates sit on the 2027 horizon.1Research file
Ethylene Oxide and Multiple Cancers
Communities near medical-equipment sterilization plants and chemical plants have sued over ethylene oxide emissions linked to leukemia, non-Hodgkin lymphoma, breast cancer, and other cancers. Sterigenics settled 870 cases involving its Willowbrook, Illinois, plant for $408 million in 2023, and another 97 cases for $31 million in April 2025. A 2022 jury awarded $363 million to a breast cancer survivor in the first case to reach trial. Cases continue against multiple companies.1Research file
Zantac and Stomach, Pancreatic, and Prostate Cancer
Zantac litigation is uneven. The federal multidistrict litigation was dismissed in 2022 after a judge excluded the plaintiffs’ scientific evidence linking ranitidine to cancer. In April 2026, a Delaware court dismissed over 80,000 additional cases. Cases remain active in California, Illinois, and Connecticut. GlaxoSmithKline reached a $2.2 billion settlement covering roughly 80,000 of its cases in October 2024. Sanofi settled about 4,000 claims for $100 million; Pfizer agreed to $250 million for about 10,000 cases. Stomach, pancreatic, and prostate cancer claims have settled in the $300,000 to $500,000 range; lower-tier claims have paid $20,000 to $75,000.1Research file
Camp Lejeune Water Contamination
The Camp Lejeune Justice Act of 2022 allowed military personnel and family members exposed to contaminated water at Marine Corps Base Camp Lejeune to file claims against the federal government. The Department of the Navy received nearly 410,000 administrative claims before the deadline closed in August 2024. As of March 2026, the Department of Justice had paid approximately $708 million, but only about 12 percent of claims qualified under the government’s Elective Option settlement framework. The Congressional Budget Office estimates total federal liability could reach at least $21 billion. Bellwether trials for leukemia and non-Hodgkin lymphoma claims are being pursued, but trial dates remain uncertain.1Research file
What You’ll Need to Prove Eligibility
Each mass tort has its own criteria, but intake almost always asks for the same three things. A confirmed diagnosis of one of the specific cancers tied to the product. Evidence of exposure during a relevant time period, which can come from employment records, purchase history, residential proximity to a facility, or military service records. And medical records connecting the diagnosis to the exposure, often including pathology reports and sometimes expert medical opinions.1Research file
Deadlines are the trap. Statutes of limitations typically run one to six years from diagnosis or from discovery of the link between the illness and the exposure, varying by state and litigation. Some programs have hard dates: the Radiation Exposure Compensation Act requires all claims by December 31, 2027. Missing the deadline bars the claim regardless of its merits.1Research file
Asbestos trust claims work on their own schedules. Each trust sets its own deadline, commonly two to three years after diagnosis, and claims can be filed with several trusts at once. Expedited review usually takes three to six months; individual review for higher compensation can take a year or more.1Research file
What Compensation Actually Looks Like
Ranges vary enormously by cancer, evidence, and jurisdiction. From the active litigations:1Research file
- Mesothelioma from asbestos: settlements average $1 million to $2 million; verdicts average $5 million to $20.7 million; trust fund claims typically yield $300,000 to $400,000 combined.
- Roundup non-Hodgkin lymphoma: the proposed 2026 settlement would pay $6,000 to $165,000 per claim. Individual trial verdicts have reached into the billions, though those are often reduced on appeal.
- Zantac tier 1 cancers (stomach, pancreatic, prostate): $300,000 to $500,000. Lower-tier claims: $20,000 to $75,000.
- Camp Lejeune leukemia: government settlement tiers from $150,000 for shorter exposures up to $450,000 for exposures longer than five years.
Settlement compensation for physical injuries is generally not taxable at the federal level, though punitive damages and interest can be treated differently. Contingency fees usually run 20 to 40 percent of the recovery. Camp Lejeune fees are capped at 20 percent for administrative settlements and 25 percent for litigated cases.1Research file
Who Actually Regulates These Services
Not many people, and not closely. The FDA does not regulate attorney advertising. The FTC has general authority over deceptive advertising but has not issued comprehensive guidance for mass tort lead generation. State bar associations regulate attorney advertising through professional conduct rules, but according to Congressional testimony, no state bar has disciplined an attorney specifically for drug-injury advertising.1Research file
The FTC’s most notable action came in September 2019, when it sent warning letters over misleading mass tort television ads. The Commission flagged scare tactics, unsubstantiated health claims, and “medical alert” framing that implies government authority. Its 2023 “Operation Stop Scam Calls” also targeted lead generators using deceptive consent practices, resulting in a $2.5 million penalty against one company and a permanent ban on its robocalling. The FCC’s “One-to-One Consent Rule” and the FTC’s ban on fake reviews are newer rules affecting how these services operate.1Research file
The practical takeaway: regulators have not built a safety net under this market. Vetting the service, and the law firm it would route you to, is on you.